Study #2018-0533
A Phase 2 Course Determining Study for Men with Hormone-Naive Metastatic Prostate Cancer (HNMPCa)
MD Anderson Study Status
Not Accepting
Treatment Agent
Abiraterone Acetate, Apalutamide, Prednisone
Description
This phase II trial studies how well abiraterone acetate, prednisone, and apalutamide work in treating patients with hormone-naive prostate cancer that has spread to other places in the body. Androgen can cause the growth of prostate cancer cells. Antihormone therapy, such as abiraterone acetate and apalutamide may lessen the amount of androgen made by the body.
Resources and Links
Phone Number: 1-877-MDA-6789
Information and next steps
Disease:
Metastatic Prostate Carcinoma, Prostate Adenocarcinoma, Prostate Carcinoma Metastatic in the Bone, Stage IV Prostate Cancer AJCC v8, Stage IVA Prostate Cancer AJCC v8, Stage IVB Prostate Cancer AJCC v8
Study phase:
Phase II
Physician name:
Paul Corn
Department:
Genitourinary Medical Oncology
For general questions about clinical trials:
1-844-902-2329
Help #EndCancer
Give Now
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.